Krisha Globals

Evenity Injection contains the active ingredient Romosozumab, a humanized monoclonal antibody that promotes bone formation while simultaneously inhibiting bone resorption. It belongs to the anti-osteoporotic agents class and is primarily indicated for the treatment of osteoporosis in postmenopausal women who are at high risk of fractures. By increasing bone mineral density and strength, Injection Evenity reduces the risk of both vertebral and non-vertebral fractures in patients with severe osteoporosis. This treatment is particularly recommended for individuals who have not responded well to other osteoporosis therapies